CoChat
Sign Up
Cited by 228Attention Deficit Hyperactivity DisorderSchizophrenia research and treatmentNeuroethics, Human Enhancement, Biomedical Innovations

The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.

Six-week, double-blind, placebo-controlled study of desipramine for adult attention deficit hyperactivity disorder

Open access
Timothy E. Wilens, Joseph Biederman, J Prince, Thomas J. Spencer, Stephen V. Faraone, R Warburton, David Schleifer, M Harding, C Linehan, DANIEL A. GELLER·1996·American Journal of Psychiatry
DOI 10.1176/ajp.153.9.1147
Open this paper in CoChat — free account

Abstract

OBJECTIVE: Despite the increasing awareness of attention deficit hyperactivity disorder (ADHD) in adults, there are a limited number of controlled pharmacologic studies of this disorder; most of the trials have focused on the psychostimulants. Because the tricyclic anti-depressant desipramine has been found to be effective in treating ADHD in pediatric groups, the authors tested its efficacy in adults with ADHD. METHOD: The authors conducted a randomized, 6-week, placebo-controlled, parallel-design study of desipramine at a target daily dose of 200 mg in 41 adult patients with DSM-III-R ADHD. They used standardized structured psychiatric instruments for diagnosis and, as the dependent variables (outcome), used separate assessments of ADHD, depressive, and anxiety symptoms at baseline and at each biweekly visit. RESULTS: There were highly significant differences in the reduction of ADHD symptoms between adults receiving desipramine and placebo. Within the desipramine-treated group, there were clinically and statistically significant differences between baseline and the week 6 end point for 1) reduction of 12 of 14 symptoms of ADHD and 2) decreases in the broad categories of hyperactivity, impulsivity, and inattentiveness. In contrast, placebo-treated patients showed no differences between baseline and end point for any of the ADHD symptoms assessed. According to strict, predefined criteria for response, 68% of desipramine-treated subjects and no subjects in the placebo group were considered positive responders. Response to desipramine was independent of dose, level of impairment, gender, or lifetime psychiatric comorbidity with anxiety or depressive disorders. CONCLUSIONS: These results, similar to findings in children and adolescents with ADHD, indicate that desipramine is effective in the treatment of ADHD in adults.

Overview

Integrity signals

Registry

Crossref · 10.1176/ajp.153.9.1147

Cites

38 of 38 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Flagged first, then by citations

Show all 38 references

Cited by

Sorted by citations

Related

See all

Metadata

Authors
Wilens, T. E., Biederman, J., Prince, J., Spencer, T. J., Faraone, S. V., Warburton, R., Schleifer, D., Harding, M., Linehan, C., & GELLER, D. A.
Affiliations
Massachusetts General Hospital (US)
ORCID
Venue
American Journal of Psychiatry
Publisher
American Psychiatric Association Publishing
Published
1996-09
Volume
153
Issue
9
Pages
1147-1153
ISSN
  • 0002-953X (ISSN-L)
  • 1535-7228
DOI
10.1176/ajp.153.9.1147
OpenAlex
W10325908
Cited by
228
References
38
Citations by year
2026: 1 · 2025: 1 · 2024: 7 · 2023: 3 · 2021: 2 · 2019: 3 · 2018: 3 · 2017: 5 · 2016: 1 · 2015: 2 · 2014: 3 · 2013: 3 · 2012: 9
FWCI
6.90
Type
journal article
Language
en
Open access
Licence
cc-by-nc-nd
Locations
  • American Journal of Psychiatry (publishedVersion)
  • PubMed (publishedVersion)
  • SUNY Digital Repository Support (State University of New York System) (submittedVersion, cc-by-nc-nd)
Funders
National Institute of Mental Health (MH-011175)
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Attention Deficit Hyperactivity Disorder
  • Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
  • Social Sciences › Arts and Humanities › Philosophy › Neuroethics, Human Enhancement, Biomedical Innovations
Keywords
desipramine, adult ADHD, tricyclic antidepressants, ADHD medication, hyperactivity, impulsivity, inattention, depressive symptoms, anxiety symptoms
MeSH terms
Adolescent, Adult, Age Factors, Ambulatory Care, Anxiety Disorders, Attention Deficit Disorder with Hyperactivity, Mental Disorders, Child, Depressive Disorder, Desipramine, Double-Blind Method, Drug Administration Schedule, Female, Follow-Up Studies, Humans, Male, Placebos, Psychiatric Status Rating Scales, Severity of Illness Index, Social Class, Wechsler Scales, Comorbidity, Treatment Outcome

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review